Acumen Pharmaceuticals Net Income Over Time
| ABOS Stock | USD 2.59 0.01 0.38% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Acumen Pharmaceuticals Performance and Acumen Pharmaceuticals Correlation. Is there potential for Biotechnology market expansion? Will Acumen introduce new products? Factors like these will boost the valuation of Acumen Pharmaceuticals. If investors know Acumen will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Acumen Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Acumen Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Acumen Pharmaceuticals' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Acumen Pharmaceuticals' market price to deviate significantly from intrinsic value.
Understanding that Acumen Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Acumen Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Acumen Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Acumen Pharmaceuticals and related stocks such as Inovio Pharmaceuticals, Opus Genetics, and Agenus Inc Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INO | (6.6 M) | (15.3 M) | (19.7 M) | (66 M) | (36.1 M) | (29.2 M) | (73.7 M) | (88.2 M) | (97 M) | (119.4 M) | (166.4 M) | (303.7 M) | (279.8 M) | (135.1 M) | (107.3 M) | (96.5 M) | (101.4 M) |
| IRD | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (24.6 M) | (56.7 M) | 17.9 M | (10 M) | (57.5 M) | (51.8 M) | (49.2 M) |
| AGEN | (18.1 M) | (23.3 M) | (11.3 M) | (30.1 M) | (42.5 M) | (87.9 M) | (127 M) | (120.7 M) | (159.7 M) | (107.7 M) | (180.9 M) | (23.9 M) | (220.1 M) | (245.8 M) | (227.2 M) | (204.5 M) | (194.3 M) |
| ALEC | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (32.5 M) | (52.2 M) | (99.8 M) | (183 M) | (28 M) | (133.3 M) | (130.4 M) | (119 M) | (107.1 M) | (112.5 M) |
| SEER | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (16 M) | (32.8 M) | (71.2 M) | (93 M) | (86.3 M) | (86.6 M) | (77.9 M) | (81.8 M) |
| MCRB | (3.1 M) | (3.1 M) | (3.1 M) | (6.1 M) | (16.7 M) | (54.8 M) | (91.6 M) | (89.4 M) | (98.9 M) | (70.3 M) | (89.1 M) | (65.6 M) | (250.2 M) | (113.7 M) | 136 K | 122.4 K | 128.5 K |
| FATE | (13.4 M) | (13.4 M) | (14.2 M) | (20.9 M) | (25.9 M) | (30 M) | (33.5 M) | (43 M) | (66.6 M) | (98.1 M) | (173.4 M) | (212.2 M) | (255.1 M) | (160.9 M) | (186.3 M) | (167.6 M) | (159.3 M) |
| VTGN | (4.8 K) | (12.2 M) | (12.9 M) | (3 M) | (13.9 M) | (47.2 M) | (10.3 M) | (14.3 M) | (24.6 M) | (20.8 M) | (17.9 M) | (47.8 M) | (59.2 M) | (29.4 M) | (51.4 M) | (46.3 M) | (44 M) |
| SPRO | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (25.5 M) | (46.1 M) | (41.7 M) | (60.2 M) | (77.5 M) | (89.8 M) | (46.4 M) | 22.8 M | (68.6 M) | (61.7 M) | (64.8 M) |
| ACTU | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (24.7 M) | (27.3 M) | (24.6 M) | (25.8 M) |
Acumen Pharmaceuticals and related stocks such as Inovio Pharmaceuticals, Opus Genetics, and Agenus Inc Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Acumen Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Acumen Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Acumen Pharmaceuticals | ABOS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1210-1220 Washington St, |
| Exchange | NASDAQ Exchange |
USD 2.59
Additional Tools for Acumen Stock Analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.